Capturing the Angel in "Angel Dust": Twenty Years of Translational Neuroscience Studies of NMDA Receptor Antagonists in Animals and Humans
Open accessThe DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Abstract
Here, we describe our collaborative efforts to use N-methyl-d-aspartate (NMDA) receptor antagonists as a translational tool to advance our understanding of the pathophysiology of schizophrenia and identify potential new targets for treatment of schizophrenia. We began these efforts in the late 1980s with a keen sense that, in both human and animal studies, we needed to move beyond the dopamine hypothesis of schizophrenia; if the dopamine hypothesis were correct, the existing dopamine antagonists should have cured the disease but they have not. We used NMDA receptor antagonists, not to produce schizophrenia, but as a tool to provide insights into effects of disturbances in glutamate synaptic function in schizophrenia. Our work has provided insights into potential mechanisms that may contribute to disrupted cortical function in schizophrenia and has helped identify potential treatment targets for the disorder. The translational nature of this study made the clinical testing of the first of these targets feasible. Advances in systems neuroscience approaches in animals and humans make new types of translational research possible; however, our concern is that the current obstacles facing translational research funding and academia-industry collaborations threaten the future progress in this field.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“Weakened defences appear to be necessary to activate redoxsensitive neuronal maturation pathways 81 .”
From Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis (2016) · cites this paper as [81]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“NFE2L2 is epigenetically repressed in cortical neurons early in development and what little NFE2L2 exists is highly unstable, leading to reduced intrinsic antioxidant defences 81,83 .”
From Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis (2016) · cites this paper as [81]
Experimental — accuracy not yet measuredThe check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“NFE2L2 is only weakly activatable in neurons 81,83”
From Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis (2016) · cites this paper as [81]
Experimental — accuracy not yet measuredIn the citing paper
“Preclinical studies have shown that disinhibition of pyramidal cells through low (subanesthetic) doses of ketamine, an NMDAR antagonist that acts preferentially on PV+ interneurons reducing the excitatory drive onto these cells 130 , normalizes inhibitory connectivity, prevents the silencing of cortical circuits, and extends the lifespan of Mecp2 mutants 131 .”
From Developmental timing and critical windows for the treatment of psychiatric disorders (2016) · cites this paper as [130]
In the citing paper
“Indeed, they express little nuclear factor erythroid 2-related factor 2 (NFE2L2, also known as NRF2), a transcription factor and master regulator of antioxidant defence genes 81,82 (Figure 5).”
From Linking early-life NMDAR hypofunction and oxidative stress in schizophrenia pathogenesis (2016) · cites this paper as [81]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
(1909) · Journal of the American Medical Association · doi:10.1001/jama.1909.02550020033007 · Cited by 7,866
Krystal, J. H. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950030035004 · Cited by 3,330
Self-citationMoghaddam, B., Adams, B., Verma, A., & Daly, D. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-08-02921.1997 · Cited by 1,793
Self-citationBremner, J. D., Randall, P., Vermetten, E., Staib, L., Bronen, R. A., Mazure, C., Capelli, S., McCarthy, G., Innis, R. B., & Charney, D. S. (1997) · Biological Psychiatry · doi:10.1016/s0006-3223(96)00162-x · Cited by 1,283
Homayoun, H., & Moghaddam, B. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2213-07.2007 · Cited by 1,231
Self-citationPatil, S. T., Zhang, L., Martenyi, F., Lowe, S. L., Jackson, K. A., Andreev, B. V., Avedisova, A. S., Bardenstein, L. M., Gurovich, I. Y., Morozova, M. A., et al. (2007) · Nature Medicine · doi:10.1038/nm1632 · Cited by 1,040
Reversal of Phencyclidine Effects by a Group II Metabotropic Glutamate Receptor Agonist in Rats
Moghaddam, B., & Adams, B. W. (1998) · Science · doi:10.1126/science.281.5381.1349 · Cited by 1,006
Self-citationStudy of a New Schizophrenomimetic Drug—Sernyl
LUBY, E. D. (1959) · Archives of Neurology And Psychiatry · doi:10.1001/archneurpsyc.1959.02340150095011 · Cited by 921
AGHAJANIAN, G. K. (1978) · Nature · doi:10.1038/276186a0 · Cited by 802
NMDA Receptor Function and Human Cognition: The Effects of Ketamine in Healthy Volunteers
Malhotra, A. (1996) · Neuropsychopharmacology · doi:10.1016/0893-133x(95)00137-3 · Cited by 680
The Glutamatergic Dysfunction Hypothesis for Schizophrenia
Coyle, J. T. (1996) · Harvard Review of Psychiatry · doi:10.3109/10673229609017192 · Cited by 568
Krystal, J. H., D'Souza, D. C., Mathalon, D., Perry, E., Belger, A., & Hoffman, R. (2003) · Psychopharmacology · doi:10.1007/s00213-003-1582-z · Cited by 530
Self-citationExome sequencing supports a de novo mutational paradigm for schizophrenia
Xu, B., Roos, J. L., Dexheimer, P., Boone, B., Plummer, B., Levy, S., Gogos, J. A., & Karayiorgou, M. (2011) · Nature Genetics · doi:10.1038/ng.902 · Cited by 466
Verma, A., & Moghaddam, B. (1996) · The Journal of Neuroscience · doi:10.1523/jneurosci.16-01-00373.1996 · Cited by 449
Self-citationJackson, M. E., Homayoun, H., & Moghaddam, B. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308455101 · Cited by 430
Self-citationAnand, A., Charney, D. S., Oren, D. A., Berman, R. M., Hu, X. S., Cappiello, A., & Krystal, J. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.3.270 · Cited by 426
Self-citationThe NMDA antagonist MK-801 causes marked locomotor stimulation in monoamine-depleted mice
Carlsson, M., & Carlsson, A. (1989) · Journal of Neural Transmission · doi:10.1007/bf01258633 · Cited by 423
Vollenweider, F. X., Leenders, K. L., Øye, I., Hell, D., & Angst, J. (1997) · European Neuropsychopharmacology · doi:10.1016/s0924-977x(96)00042-9 · Cited by 413
Cognitive Dysfunction in Schizophrenia: Convergence of γ-Aminobutyric Acid and Glutamate Alterations
Lewis, D. A., & Moghaddam, B. (2006) · Archives of Neurology · doi:10.1001/archneur.63.10.1372 · Cited by 404
Self-citationBringing Order to the Glutamate Chaos in Schizophrenia
Moghaddam, B. (2003) · Neuron · doi:10.1016/s0896-6273(03)00757-8 · Cited by 403
Self-citationMoghaddam, B., & Bunney, B. S. (1990) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1990.tb01230.x · Cited by 402
Self-citationAdams, B., & Moghaddam, B. (1998) · The Journal of Neuroscience · doi:10.1523/jneurosci.18-14-05545.1998 · Cited by 365
Self-citationKrystal, J. H., Perry, E. B., Gueorguieva, R., Belger, A., Madonick, S. H., Abi-Dargham, A., Cooper, T. B., MacDougall, L., Abi-Saab, W., & D’Souza, D. C. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.9.985 · Cited by 317
Self-citationEffects of Ketamine on Thought Disorder, Working Memory, and Semantic Memory in Healthy Volunteers
Adler, C., Goldberg, T., Malhotra, A., Pickar, D., & Breier, A. (1998) · Biological Psychiatry · doi:10.1016/s0006-3223(97)00556-8 · Cited by 304
Stone, J. M., Dietrich, C., Edden, R., Mehta, M. A., De Simoni, S., Reed, L. J., Krystal, J. H., Nutt, D., & Barker, G. J. (2012) · Molecular Psychiatry · doi:10.1038/mp.2011.171 · Cited by 295
Self-citationHeninger, G. R. (1984) · Archives of General Psychiatry · doi:10.1001/archpsyc.1984.01790150088012 · Cited by 279
Krystal, J. H., Abi-Saab, W., Perry, E., D’Souza, D. C., Liu, N., Gueorguieva, R., McDougall, L., Hunsberger, T., Belger, A., Levine, L., et al. (2005) · Psychopharmacology · doi:10.1007/s00213-004-1982-8 · Cited by 272
Self-citationCartmell, J., Monn, J. A., & Schoepp, D. D. (1999) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)35084-0 · Cited by 269
Kinon, B. J., Zhang, L., Millen, B. A., Osuntokun, O. O., Williams, J. E., Kollack-Walker, S., Jackson, K., Kryzhanovskaya, L., & Jarkova, N. (2011) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e318218dcd5 · Cited by 256
Interactive effects of subanesthetic ketamine and haloperidol in healthy humans
Krystal, J. H., D'Souza, D. C., Karper, L. P., Bennett, A., Abi-Dargham, A., Abi-Saab, D., Cassello, K., Bowers Jr., M. B., Vegso, S., Heninger, G. R., et al. (1999) · Psychopharmacology · doi:10.1007/s002130051049 · Cited by 243
Self-citationNegative schizophrenic symptomatology and the PCP (phencyclidine) model of schizophrenia.
Javitt, D. (1987) · PubMed · Cited by 240
Krystal, J. (1999) · Harvard Review of Psychiatry · doi:10.1093/hrp/7.3.125 · Cited by 232
Self-citationSCHOEPP, D. D., JOHNSON, B. G., WRIGHT, R. A., SALHOFF, C. R., MAYNE, N. G., WU, S., COCKERHAM, S. L., PAUL BURNETT, J., BELEGAJE, R., BLEAKMAN, D., et al. (1997) · Neuropharmacology · doi:10.1016/s0028-3908(96)00160-8 · Cited by 225
Kinney, G. G., Burno, M., Campbell, U. C., Hernandez, L. M., Rodriguez, D., Bristow, L. J., & Conn, P. J. (2003) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.103.048702 · Cited by 219
Ghoneim (1985) · doi:10.1097/00004714-198504000-00003 · Cited by 196
Targeting metabotropic glutamate receptors for treatment of the cognitive symptoms of schizophrenia
Moghaddam, B. (2004) · Psychopharmacology · doi:10.1007/s00213-004-1792-z · Cited by 189
Self-citationNeurotransmitter aberrations in schizophrenia: New perspectives and therapeutic implications
Carlsson, A., Hansson, L. O., Waters, N., & Carlsson, M. L. (1997) · Life Sciences · doi:10.1016/s0024-3205(97)00228-2 · Cited by 187
Interactive effects of subanesthetic ketamine and subhypnotic lorazepam in humans
Krystal, J. H., Karper, L. P., Bennett, A., D'Souza, D. C., Abi-Dargham, A., Morrissey, K., Abi-Saab, D., Bremner, J. D., Bowers Jr., M. B., Suckow, R. F., et al. (1998) · Psychopharmacology · doi:10.1007/s002130050503 · Cited by 184
Self-citationThe effects of phencyclidine and N-allylnormetazocine on midbrain dopamine neuronal activity
Freeman, A. S., & Bunney, B. S. (1984) · European Journal of Pharmacology · doi:10.1016/0014-2999(84)90404-7 · Cited by 177
Buchanan, R. W., Keefe, R. S. E., Lieberman, J. A., Barch, D. M., Csernansky, J. G., Goff, D. C., Gold, J. M., Green, M. F., Jarskog, L. F., Javitt, D. C., et al. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.09.052 · Cited by 172
Marek, G. J., Behl, B., Bespalov, A., Groß, G., Lee, Y., & Schoemaker, H. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.059865 · Cited by 164
Homayoun, H., Jackson, M. E., & Moghaddam, B. (2005) · Journal of Neurophysiology · doi:10.1152/jn.00875.2004 · Cited by 137
Self-citationLamotrigine as Add-On Therapy in Schizophrenia: Results of 2 Placebo-Controlled Trials
Goff, D. C., Keefe, R., Citrome, L., Davy, K., Krystal, J. H., Large, C., Thompson, T. R., Volavka, J., & Webster, E. L. (2007) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31815abf34 · Cited by 120
Self-citationTesting the glutamate hypothesis of schizophrenia
Gordon, J. A. (2009) · Nature Neuroscience · doi:10.1038/nn0110-2 · Cited by 98
DEXTROMETHORPHANAS A SAFE PROBE FOR DEBRISOQUINE HYDROXYLATION POLYMORPHISM
Kupfer, A., Schmid, B., Preisig, R., & Pfaff, G. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92591-1 · Cited by 90
Liu, J., & Moghaddam, B. (1995) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(25)10607-1 · Cited by 89
Self-citationD'Souza, D. C., Singh, N., Elander, J., Carbuto, M., Pittman, B., de Haes, J. U., Sjogren, M., Peeters, P., Ranganathan, M., & Schipper, J. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.295 · Cited by 66
Effects of zotepine, haloperidol and clozapine on MK-801-induced stereotypy and locomotion in rats
Gattaz, W. F., Schummer, B., & Behrens, S. (1994) · Journal of Neural Transmission · doi:10.1007/bf01294789 · Cited by 42
Homovanillic acid in rat caudate and prefrontal cortex following phencyclidine and amphetamine
Bowers, M. B., & Hoffman, F. J. (1984) · Psychopharmacology · doi:10.1007/bf00432043 · Cited by 42
CONGENITAL OBSTRUCTION OF THE LARYNX AND PHARYNX
New, G. B. (1923) · JAMA · doi:10.1001/jama.1923.02650050017006 · Cited by 16
Tost, H., & Meyer‐Lindenberg, A. (2011) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.03.013 · Cited by 9
CHLORHEXIDINE: A WHO ESSENTIAL DRUG
Denton, G. W. (1984) · The Lancet · doi:10.1016/s0140-6736(84)92588-1 · Cited by 8
Dm, D. (1947) · PubMed · Cited by 6
Krystal, J. H., & D’Souza, D. C. (2001) · Biological Psychiatry · doi:10.1016/s0006-3223(01)01258-6 · Cited by 5
Self-citation
Research works printed but not linked: 6
- 1959, JAMA, 81, 363
- 1990, Journal of Neuroscience, 54, 1755
- 24. Jackson M, Homayoun H, Moghaddam B. NMDA receptor hypofunction produces concomitant firing rate potentiation and burst activity reduction in the prefrontal cortex Proc Natl Acad Sci USA 2004;101:8467–8472 [DOI] [PMC free article] [PubMed] [Google Scholar]
- 41. Homayoun H, Jackson ME, Moghaddam B. Activation of metabotropic glutamate 2/3 receptors reverses the effects of NMDA receptor hypofunction on prefrontal cortex unit activity in awake rats J Neurophysiol. 2005;93:1989–2001 [DOI] [PubMed] [Google Scholar]
- 43. Marek GJ, Behl B, Bespalov AY, Gross G, Lee Y, Schoemaker H. Glutamatergic (N-methyl-D-aspartate receptor) hypofrontality in schizophrenia: too little juice or a miswired brain? Mol Pharmacol. 2010;77:317–326 [DOI] [PubMed] [Google Scholar]
- 45. Kinney G, Burno M, Campbell U, et al. Metabotropic glutamate subtype 5 receptors modulate locomotor activity and sensorimotor gating in rodents J Pharmacol Exp Therap 2003;306:116–123 [DOI] [PubMed] [Google Scholar]
Cited by
Zebrafish as an emerging model for studying complex brain disorders
Kalueff, A. V., Stewart, A. M., & Gerlai, R. (2014) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2013.12.002 · Cited by 1,182
Brisch, R., Saniotis, A., Wolf, R., Bielau, H., Bernstein, H.-G., Steiner, J., Bogerts, B., Braun, A. K., Jankowski, Z., Kumaritlake, J., et al. (2014) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2014.00047 · Cited by 517
“A new focus on glutamatergic signaling mediated by NMDA and metabotropic receptors may benefit new drug developments [review by Field et al. (156); Javitt (139); Matosin and Newell (157); Moghadam and Krystal (158); Noetzel et al. (159)].”
BackgroundGlutamate hypothesis in schizophrenia
Uno, Y., & Coyle, J. T. (2019) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12823 · Cited by 367
“The existence of binding sites for ketamine and PCP were described in 1979 followed by reports in the early 1980s that they are noncompetitive antagonists of the NMDA subtype of glutamate receptor.(33) Based on clinical observations of patients intoxicated with PCP and ketamine and careful laboratory studies of the ef…”
BackgroundAuditory dysfunction in schizophrenia: integrating clinical and basic features
Javitt, D. C., & Sweet, R. A. (2015) · Nature Reviews Neuroscience · doi:10.1038/nrn4002 · Cited by 367
Developmental timing and critical windows for the treatment of psychiatric disorders
Marín, O. (2016) · Nature Medicine · doi:10.1038/nm.4225 · Cited by 374
Metadata
- Authors
- Moghaddam, B., & Krystal, J. H.
- Affiliations
- University of Pittsburgh (US)
- Yale University (US)
- Corresponding author
- Moghaddam, B.
- Venue
- Schizophrenia Bulletin
- Publisher
- Oxford University Press (OUP)
- Published
- 2012-08-16
- Volume
- 38
- Issue
- 5
- Pages
- 942-949
- ISSN
- 0586-7614 (ISSN-L)
- 1745-1701
- PMC
- PMC3446228
- OpenAlex
- W2112492148
- Cited by
- 238
- References
- 54
- Citations by year
- 2026: 11 · 2025: 10 · 2024: 10 · 2023: 9 · 2022: 13 · 2021: 16 · 2020: 12 · 2019: 16 · 2018: 25 · 2017: 23 · 2016: 24 · 2015: 28 · 2014: 29 · 2013: 11 · 2012: 1
- FWCI
- 2.98
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- Schizophrenia Bulletin (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Eli Lilly and Company
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Keywords
- NMDA receptor antagonists, schizophrenia
- MeSH terms
- Allosteric Regulation, Animals, Cerebral Cortex, Disease Models, Animal, Dopamine, Emotions, Humans, Ketamine, Neurosciences, Brief Psychiatric Rating Scale, Phencyclidine, Psychoses, Substance-Induced, Schizophrenia, Synapses, Antipsychotic Agents, Receptors, N-Methyl-D-Aspartate, Receptors, Dopamine D2, Receptors, Metabotropic Glutamate, Glutamic Acid, Translational Research, Biomedical, Receptor, Metabotropic Glutamate 5
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.